Principais highlights do Congresso do American College of Cardiology 2022

Escrito por: Adriana Toledo Mazza em 11 de abril de 2022

1 min de leitura

Os Drs. Renato Lopes, Ariane Macedo e Pedro Barros e Silva, se reuniram, em formato de mesa-redonda, para discutir os estudos clínicos que foram destaques durante o Congresso da ACC 2022. No vídeo, os especialistas apresentam as inovações desses estudos e suas possíveis repercussões na prática clínica do médico cardiologista. Vale a pena assistir e conferir o conteúdo completo!

Quer continuar lendo?

Login Cadastre-se

Referências

  1. Alan Tita et al., Antihypertensive Therapy For Mild Chronic Hypertension and Pregnancy Outcomes: A Pragmatic Multicenter RCT. Presented at the American College of Cardiology’s 71st Annual Scientific Session. 2022.

  2. Tariq Ahmad et al., A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF. J Am Coll Cardiol 2022;Apr 3. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022. 

  3. Mikhail Kosiborod et al., Effects Of Empagliflozin On Symptoms, Physical Limitations And Quality Of Life In Patients Hospitalized For Acute Heart Failure- Results From The EMPULSE Trial. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022. 

  4. Milind Y. Desai et al., Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022. 

  5. Dr. Deepak L. Bhatt et al., Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, And Stroke In The Scored Trial. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April, 2022. 

  6. Gregory D. Lewis The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April, 2022. 

  7. Lorenz Raber et al., Effects Of Alirocumab On Coronary Atherosclerosis Assessed By Serial Multimodality Intracoronary Imaging In Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial (PACMAN AMI). Presented at the American College of Cardiology’s 71st Annual Scientific Session. 2022. 

  8. Duk-Woo Park, et al., Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022. 

  9. Dr. Manesh R. Patel et al., Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing The Safety Of The Oral FXIa Inhibitor Asundexian With Apixaban In Patients With Atrial Fibrillation: PACIFIC AF. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022. 

Sobre o autor

Adriana Toledo Mazza

Editora-chefe